biotech / news / / Livemint
Vaccine developer Bharat Biotech International Ltd is exploring to raise over $500 million through an initial public offering, according to a Bloomberg report.
Bharat Biotech is considering raising over $500 million via an initial public offering.
KEY POINTS
- Bharat Biotech signed a Technology Transfer Agreement with Biofabri to make and supply MTBVAC.
- Bharat Biotech will produce MTBVAC for tuberculosis for over 70 countries in Africa and Southeast Asia.
- Biovet, a Bharat Biotech group company, received the world’s first LSD vaccine license for dairy cattle.
COMPANIES
Summarized by Newsio from Livemint. How we summarize →